The 2026 Mazza et al. study in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging (n=159; 81 bipolar, 78 MDD; observational multivariate analysis) maps a clinically actionable pathway: insulin resistance and leptin dysregulation correlate with reduced gray-matter volume in prefrontal and hippocampal regions, driving memory and executive deficits exclusively in bipolar patients. This association strengthens with lifetime manic episodes, suggesting cumulative illness burden amplifies metabolic neurotoxicity via inflammation and impaired neuronal insulin signaling. Original coverage underplays causality gaps and intervention potential; unlike RCTs, this cross-sectional design cannot establish directionality, yet patterns align with prior evidence that brain insulin resistance precedes structural change. Synthesizing with a 2023 RCT of metformin in bipolar (n=120; 12-week, double-blind) showing modest gains in verbal memory alongside HOMA-IR reduction, and a 2021 longitudinal cohort (n=1,842) linking midlife insulin resistance to accelerated cognitive decline in mood disorders, reveals a modifiable node mainstream psychiatry ignores. Targeting peripheral and central insulin pathways with repurposed agents or lifestyle protocols could decouple metabolic burden from neurodegeneration, an angle the source overlooks amid its diagnostic-comparison focus. No conflicts declared; sample limits generalizability but highlights specificity to bipolar.